“…Therefore, changes in the molecular architecture of porphyrins by introducing polar and nonpolar substituients [ 14 , 15 ] or metallic ions [ 15 ] can improve their photophysical characteristics and pharmacological efficacy. Consequently, as part of our ongoing research on obtaining unsymmetrical meso -tetrasubstituted phenyl porphyrins [ 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 ], we designed and synthesized three new unsymmetrical meso -tetrasubstituted phenyl porphyrins whose general structure is presented in Figure 1 : 5-(4-hydroxy-3-methoxyphenyl)-10,15,20- tris -(4-acetoxy-3-methoxyphenyl)porphyrin ( P2.2 ), Zn(II)-5-(4-hydroxy-3-methoxyphenyl)-10,15,20- tris -(4-acetoxy-3-methoxyphenyl)porphyrin ( Zn(II)2.2 ), Cu(II)-5-(4-hydroxy-3-methoxyphenyl)-10,15,20- tris -(4-acetoxy-3-methoxyphenyl)porphyrin ( Cu(II)2.2 ). These compounds are intended to be developed as theranostic agents for photodynamic therapy (PDT) in cancer.…”